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Abstract
The p140Cap adaptor protein is a scaffold molecule encoded by the SRCIN1 gene, which is physiologically expressed in 
several epithelial tissues and in the neurons. However, p140Cap is also strongly expressed in a significant subset of cancers 
including breast cancer and neuroblastoma. Notably, cancer patients with high p140Cap expression in their primary tumors 
have a lower probability of developing a distant event and ERBB2-positive breast cancer sufferers show better survival. In 
neuroblastoma patients, SRCIN1 mRNA levels represent an independent risk factor, which is inversely correlated to disease 
aggressiveness. Consistent with clinical data, SRCIN1 gain or loss of function mouse models demonstrated that p140Cap may 
affect tumor growth and metastasis formation by controlling the signaling pathways involved in tumorigenesis and metastatic 
features. This study reviews data showing the relevance of SRCIN1/p140Cap in cancer patients, the impact of SRCIN1 status 
on p140Cap expression, the specific mechanisms through which p140Cap can limit cancer progression, the molecular func-
tions regulated by p140Cap, along with the p140Cap interactome, to unveil its key role for patient stratification in clinics.
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Abbreviations
SRCIN1  Src Kinase Signaling Inhibitor 1
p140Cap  Cap: p130Cas-associated protein
BC  Breast cancer
NB  Neuroblastoma
Introduction
p140Cap, also known as p130Cas-associated protein or 
SNIP (SNAP-25 Interacting Protein), is a scaffold molecule 
involved in the formation of multi-protein complexes [1–4]. 
The p140Cap protein is encoded by the Src Kinase Signaling 
Inhibitor 1 gene (SRCIN1), located on chromosome 17q12 
[4]. Structurally, p140Cap is a highly hydrophilic protein, 
which does contain neither a signal sequence nor a puta-
tive transmembrane domain [1]. Its amino acid sequence 
includes a tyrosine-rich domain, a putative actin-binding 
site, two proline-rich domains containing multiple PPXY 
and PXXP involved in protein–protein interactions with the 
SH3 domains, a coil-coiled region and two C-terminal highly 
charged regions [1, 3]. Furthermore, p140Cap includes sev-
eral serine, threonine and tyrosine residues that upon phos-
phorylation could serve as binding sites for proteins involved 
in the signaling network [5]. In the human, p140Cap shares 
up to 60% homology and 40% identity (when aligned with 
BLASTp) only with the Sickle-Tail (SKT) protein, the latter 
encoded by the human KIAA1217 gene [6, 7]. The p140Cap 
protein is physiologically highly expressed in the cerebral 
cortex and in the cerebellum, and poorly expressed in sev-
eral epithelial tissues. Indeed, p140Cap was first discovered 
Cellular and Molecular Life Sciences
Vincenzo Salemme, Costanza Angelini, and Jennifer Chapelle 
contributed equally to this work
 * Ugo Ala 
 ugo.ala@unito.it
 * Paola Defilippi 
 paola.defilippi@unito.it
1 Department of Molecular Biotechnology and Health 
Science, Università degli Studi di Torino, Via Nizza 52, 
10126 Torino, Italy
2 Department of Veterinary Sciences, Università degli Studi di 
Torino, Largo Paolo Braccini 2, 10095 Grugliasco, TO, Italy
 V. Salemme et al.
1 3
as an interactor of SNAP-25 in the rat brain [1]. Its role in 
neurons was further evidenced by several groups, on account 
of the use of the p140Cap knock-out mouse model [8–10]. 
Subsequently, the human orthologue of rat SNIP proteins 
was identified by mass spectrometry in epithelial cells as 
the 140 kDa KIAA1684 protein indirectly associated with 
p130Cas through the last 217 amino acids of p140Cap 
and the amino acids 544–678 of p130Cas [3]. Indeed, 
the p140Cap C-terminal region (amino acids 1000–1217) 
directly binds to the SH3 domain of Src kinase, which in 
turn directly binds to p130Cas [11]. Despite these data, 
p140Cap involvement in tissues other than the brain has 
not been deeply investigated to date. This study reviews the 
expanding amount of data on the p140Cap role in human 
cancer published following our previous review [2]. Overall, 
these data underline the fact that a positive p140Cap status 
correlates with increased cancer patient survival. Therefore, 
the genomic status of SRCIN1 gene and the role of its post-
transcriptional regulation in cancer are illustrated. Moreo-
ver, both the molecular mechanisms controlled by p140Cap 
and the functional features of p140Cap tumor-expressing 
cells are underlined as well as its scaffold role based on the 
analysis of specific binding proteins and of the interactome 
in cancer cells.
Genomic organization of the SRCIN1 gene
The human SRCIN1 gene which consists of 27 exons is 
located on chromosome 17q12, and is highly conserved in 
mammals, especially in primates but also in mice, rats, dogs, 
and cows [4]. At least six different coding transcripts are 
reported as deriving from the SRCIN1 gene in the Ensem-
ble database. Furthermore, human SRCIN1-flanking regions 
contain several genes involved in tumor initiation and pro-
gression, such as ERBB2 (17q12), BRCA1 (17q21), retinoic 
acid receptor-α (RARA ; 17q21) and signal transducer and 
activator of transcription 3 (STAT3; 17q21). These genes 
are often amplified or undergo a gain of function role in 
human tumors, suggesting that SRCIN1 might also be sub-
jected to such chromosome rearrangements [12]. Therefore, 
the SRCIN1 gene-containing region is a typical example of 
a synteny block that shares a common order of homologous 
genes between human and mouse genomes. Moreover, the 
structure of human and mouse SRCIN1 genes are highly 
comparable [3]. Data on p140Cap gene expression regu-
lation are currently limited, in that, amplification or rear-
rangements can occur in this region but additional epigenetic 
mechanisms can also account for altered p140Cap protein 
expression in cancer (see below).
SRCIN1/p140Cap physiological expression
mRNA expression data for 37 different normal tissues 
obtained from RNA deep sequencing, as provided by the 
Human Protein Atlas (HPA) database, https ://www.prote 
inatl as.org/ENSG0 00002 77363 -SRCIN 1/tissu e, show 
high expression in the brain, the salivary glands and the 
skin. Protein expression data for 44 normal human tissues, 
based on immunohistochemistry (IHC) profiling, showed 
that p140Cap is highly expressed in the brain and in the 
testes, while it is barely expressed in the thyroid and the 
parathyroid glands, the salivary glands, the pancreas, the 
nasopharynx, the bronchi and the lungs, the kidneys, the 
fallopian tubes, the breast, the heart muscle and smooth 
muscle. p140Cap expression in different healthy tissues 
versus tumor counterparts have also been analyzed in the 
studies which report its post-transcriptional regulation by 
miRNAs (see below).
Furthermore, in the pancreas of Wistar rats, p140Cap 
has been found enriched in beta cells by IHC, revealing 
a cytoplasmic granular pattern [13]. Instead, in normal 
human breast tissues deriving from reduction mammo-
plasty by IHC, a selective expression of p140Cap has been 
detected in the alveolar luminal cells, whereas no stain-
ing was visible in ductal epithelial or myoepithelial cells 
[14]. Interestingly, the characterization of the MMTV-
p140Cap transgenic mouse model, overexpressing the 
p140Cap cDNA under the MMTV promoter in the mam-
mary gland, showed that p140Cap overexpression does not 
affect mammary gland development and differentiation but 
only induces a slight delay in post weaning lobular involu-
tion [15]. Further investigations are of course necessary to 
better understand the role of p140Cap in mammary gland 
physiology. A more detailed analysis of p140Cap expres-
sion and function in physiological conditions is available 
for the brain. p140Cap is abundantly expressed in the cer-
ebellum and the telencephalon, including the hippocam-
pus, neocortex, entorhinal cortex, visual cortex [16] and 
in the nucleus accumbens [17, 18]. p140Cap subcellular 
localization in neurons has been detected at the synaptic 
level, both in pre- and postsynaptic compartments [16, 
19]. In the post-synapse, p140Cap plays a key role in actin 
remodeling and in the regulation of dendritic spine mor-
phology besides acting as a hub for the formation of post-
synaptic complexes following the interaction with various 
proteins, underlying a potential role in these compartments 
[8, 9, 20, 21].
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p140Cap and its binding partners
p140Cap protein structure and modifications
p140Cap shares some features with the “Intrinsic Dis-
order Proteins” (IDPs) containing Intrinsically Disor-
dered Regions (IDRs), which are amino acid sequences 
which cannot fold spontaneously into stable, well-defined 
globular three-dimensional structures and often remain 
disordered and fluctuate rapidly from coils to collapsed 
globules [22, 23], as evidenced by the Phyre2 database 
(Protein Homology/analogY Recognition Engine V 2.0), 
which revealed 28% alpha helices, 2% beta strands and 
75–77% disordered sequences. Consistently, similar fea-
tures were confirmed downloading data from the Intrinsic 
Protein Disorder Prediction web server [24] DisEMBL 
https ://dis.embl.de/, sequence ID: NP_079524.2). Fig-
ure 1 confirms the presence of many IDRs, especially in 
the C-terminal region, and in the region between amino 
acids 300 and 600, according to three different criteria 
(loops/coils, hot loops and missing coordinates) used as 
prediction parameters. Scaffold proteins selectively bring 
together specific proteins within signaling pathways to 
facilitate and promote interactions between them [25]. In 
this context, mainly disordered regions of p140Cap could 
allow interactions with alternative binding partners to pro-
mote specific interactions among signaling proteins.
The in vivo phosphorylation of p140Cap was assessed 
by phosphorylation-directed multistage tandem mass spec-
trometry  (pdMS3), in human breast cancer cells [5]. The 
analysis revealed the presence of three peptides containing 
phosphorylated serine residues (namely RGpSDELTVPR, 
RFpSNVGLVHTSER, and TEKPSKpSPPPPPPR). Among 
them, serine S45 and S987 are conserved in human and 
mouse p140Cap sequences and have been previously iden-
tified in murine phosphoproteomic screening investigations 
(https ://www.unipr ot.org/unipr ot/Q9QWI 6), suggesting 
the relevance of these phosphorylation sites across species, 
even if their functional role has not yet been unraveled [5]. 
 pdMS3 analysis of p140Cap also revealed the presence of 
tyrosine phosphorylated residues, consistent with previous 
data showing that p140Cap is phosphorylated on tyrosine 
residues upon integrin-mediated adhesion or EGF receptor 
activation in epithelial cells [3]. In particular, one tyrosine 
residue in the sequence 392-GEGLpYADPYGLLHEGR-407 
(briefly called EGLYA) has also been found phosphorylated 
Fig. 1  p140Cap and intrinsic disorder. Disorder probability of 
p140Cap human amino acid sequence (sequence ID: NP_079524.2), 
with DisEMBL computational tool. Figure downloaded from: Dis-
EMBL https ://dis.embl.de/, sequence ID: NP_079524, Intrinsic 
Protein Disorder Prediction 1.52). Predictions are shown accord-
ing to each of the three different criteria to define the disorder level 
of protein residues, namely: loops or coils (blue line): loop assign-
ment can be used as a necessary but not sufficient requirement for a 
disorder; -hot loops (red lines): constitute a subset of loops having a 
high degree of mobility as determined by C-alpha temperature (B-) 
factors. It follows that highly dynamic loops should be considered a 
protein disorder; missing coordinates in X-ray structure as defined by 
REMARK465 entries in PDB (green lines). Non-assigned electron 
densities in X-ray 3D structures most often reflect intrinsic disorder, 
and can be used in disorder predictions. For more detail, see [24]. 
The predicted probabilities are shown as curves along the sequences; 
scores should be compared to the corresponding random expectation 
value (dotted lines)
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in the murine brain by a large-scale identification assay 
for tyrosine phosphorylation sites [26]. Noteworthy is the 
fact that p140Cap also harbors another sequence, similar 
to EGLYA, which is EPLYA (Y264). Both “EPLYA” and 
“EGLYA” tyrosine residue-containing sequences are con-
served in humans, mice and rats (https ://www.phosp hosit 
e.org) and have been identified as the main sites for tyros-
ine phosphorylation [5]. In addition, p140Cap ability to act 
as a negative regulator of cell migration and proliferation 
mainly resides in these phosphorylated tyrosine residues 
[27]. Mechanistically, these two sequences were shown to 
be the major substrates for the Abelson (Abl) kinase, which 
controls actin remodeling, cell motility and adhesion and 
cytoskeleton dynamics [28, 29] in HEK-293 cells [5]. It is 
worth highlighting that both EPLYA and EGLYA sequences 
are analogous to the EPIYA motif, previously described in 
the bacterial CagA protein involved in Helicobacter Pylori 
pathogenesis [30], where the phosphorylated CagA EPIYA 
sequence can associate with Csk SH2 domain, resulting in 
Csk membrane recruitment with subsequent inhibition of Src 
Family Kinases (SFK) [31, 32]. The EPIYA motif has simi-
lar functions in the mammalian Pragmin/SgK223 protein 
[32, 33]. Consistently with these data, the tyrosine included 
in both EGLYA and EPLYA sequences in p140Cap plays a 
crucial role in p140Cap interaction with the Csk kinase [5] 
(see Fig. 2). In this scenario, p140Cap takes part in a mac-
romolecular complex activating Csk consequently leading to 
inhibition of Src and downstream signaling as well as cell 
motility and invasion [11]. Thus, expression of proteins such 
as p140Cap or Pragmin, which contain EPIYA-like motifs, 
could interfere with Csk activation [34] and/or localization 
[33], finely tuning SFK activity inside the cells.
p140Cap‑interacting proteins
In addition to Src and Csk, p140Cap also binds to Beta-
catenin through the 351–1051 amino-acid portion [10]. The 
terminal proline-rich domain of p140Cap associates with 
Vinexin [16], and Cortactin, a Src kinase substrate and 
an F-actin-binding protein [8, 35]. A short 92 amino acid 
C-terminal region (aa 1124–1216) also directly interacts 
with EB3, a member of the microtubule plus-end tracking 
protein EB family in the brain [8]. p140Cap has also been 
found in interactome studies performed both in mouse and 
human samples (BioGRID https ://thebi ogrid .org/20776 8/ 
and https ://thebi ogrid .org/12327 5/ respectively). p140Cap 
was found specifically present in interactome of PPP1R9B 
(protein phosphatase 1 regulatory subunit 9B) [24], SNCA 
(synuclein, alpha) [36], YWHAE (tyrosine 3-monooxy-
genase/tryptophan 5-monooxygenase activation protein) 
[37], LNX1 (ligand of numb-protein X1) [38] and AGAP2 
(ArfGAP with GTPase domain) [39], from mouse samples. 
p140Cap was also identified in the interactome of NUFIP1 
(nuclear fragile X mental retardation protein-interacting 
protein) [40, 41], BCAS4 (breast carcinoma amplified 
sequence 4) [41], ESR2 (estrogen receptor 2) [42], from 
human samples.
SRCIN1/p140Cap expression in human tumors 
correlates with good prognosis
The SRCIN1 gene status in cancer has been downloaded as 
shown in Fig. 3, from the cBioPortal for Cancer Genom-
ics, https ://www.cbiop ortal .org, which provides visualiza-
tion, analysis and download of large-scale cancer genomics 
datasets, including the TCGA repository. Figure 3 groups 
the tumors in which SRCIN1 has been found as amplified 
(red), mutated (green) or deleted (blue), indicating that the 
SRCIN1 gene can undergo several alterations in many cancer 
cohorts, including breast cancer.
(A) Breast Cancer. The likelihood that expression and 
genomic profiling of SRCIN1/p140Cap might impact on the 
disease was first evaluated in human breast cancer (BC), one 
of the most common cancers with more than 2 million new 
Fig. 2  p140Cap structure and main interactors. p140Cap consists 
of an N-terminal tyrosine-rich region (Tyr-rich), an actin-binding 
domain (ABD), a proline rich domain (Pro1), a coil-coiled region 
(C1-C2), two domains rich in charged amino acids (CH1, CH2) and 
a C-terminal proline-rich domain (Pro2). Lipidation (Myristoyla-
tion, Myr) and functional tyrosine phosphorylation (PY) EPLYA and 
EGLYA are show. The binding regions of Csk, β-Catenin, Vinexin, 
EB3, Cortactin, p130Cas and Src are shown by the red lines
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cases in 2018 and 450,000 deaths each year worldwide [43, 
44]. Clinically, BC is classified into three basic therapeutic 
groups as follows: estrogen-receptor (ER) positive, ERBB2 
(also called HER2)-positive, and triple-negative, lacking 
expression of ER, progesterone-receptor (PgR) and ERBB2 
[43]. In BC, p140Cap expression was linked to a less aggres-
sive disease [14]. Interestingly, 94.8% aggressive G3 tumors, 
87% node positive, 86.5% tumors with a high mitotic count, 
and 76% highly proliferative tumors (revealed by the Ki67 
staining marker) lose p140Cap expression, indicating that 
the most aggressive BCs do not express p140Cap, showing 
an inverse correlation with malignancy. Moreover, expres-
sion of p140Cap on a consecutive cohort of 622 invasive 
BCs showed that positive p140Cap status (with an IHC 
score ≥ 1) is associated with good prognosis markers, such 
as negative lymph node status, ER and PgR-positive status, 
small tumor size, low grade, low proliferative status, and 
ERBB2-positive status. Positive p140Cap status is also asso-
ciated with BC molecular subtypes, being expressed in more 
than 85% Luminal A, 77% Luminal B and only 56% Triple-
Negative tumors [15]. In the subgroup of ERBB2-amplified 
BC, a high p140Cap status predicts a significantly lower 
probability of developing a distant event and of death from 
BC (Fig. 4, panel a). By contrast, no significant difference is 
observed in patients who did not harbor ERBB2 amplifica-
tion. In conclusion, p140Cap expression is associated with 
reduced risk of metastasis (and death from cancer), in the 
ERBB2-amplified subgroup of BCs, suggesting a possible 
role of p140Cap in counteracting the migratory and/or meta-
static ability of ERBB2-amplified cancer cells.
(B) Neuroblastoma. In addition to BC, the relevance 
of p140Cap has been deeply investigated in Neuroblas-
toma (NB), a complex disease with different outcomes and 
responsible for a large proportion of deaths due to cancer 
in childhood [45, 46]. Primary NBs originate from genetic 
abnormalities in the neural crest-derived sympathoadrenal 
cells. Bearing in mind the functional role of p140Cap in 
differentiated neural cells [8, 9], p140Cap was detected 
by IHC in the medulla of normal human neonatal adrenal 
glands [47], indicating that p140Cap is expressed in the 
main site of origin of NBs. The Kaplan–Meier analysis of 
SRCIN1 gene expression on the R2 platform, containing 
gene expression profiles and clinical information of 498 
NB cases compared to overall survival (OS) and event-free 
survival (EFS), showed that high SRCIN1 expression was 
significantly associated with good prognosis (403 patients) 
Fig. 3  Alteration frequencies of SRCIN1 gene in cancer. Frequencies 
of SRCIN1 gene alterations in various types of cancer included in the 
TCGA PanCancer Atlas Studies. Mutations, deep deletions, amplifi-
cations and multiple alterations are shown in different colors. Figure 
download from: cBioPortal for Cancer Genomics (https ://www.cbiop 
ortal .org/)
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whereas low expression was observed in 95 poor prognosis 
patients (Fig. 4, panel b). Moreover, high SRCIN1 mRNA 
expression was found in secondary event-free survival (321 
patients) while a low expression was significantly associated 
with reduced secondary event-free survival (177 patients) 
leading to the conclusion that SRCIN1 is a prognostic risk 
factor for NB. The International Neuroblastoma Staging 
System (INSS) defines 5 stages of NB progression [48], 
from Stages 1 and 2 (localized tumor, without lymph node 
involvement) to Stage 3 and Stage 4 (metastatic disease, with 
dissemination in distant organs). Stage 4S specifies that in 
children 1-year old or younger, a metastatic disease which 
may undergo spontaneous regression is usually associated 
with 90% survival rate at 5 years. Stage (st) 4 tumors have 
a significantly lower expression of SRCIN1 mRNA relative 
to st1, st2, st3, st4s groups, supporting the conclusion that 
SRCIN1 mRNA expression is higher in patients with low 
metastatic spread. Moreover, SRCIN1 mRNA expression is 
a favorable prognostic factor, both in terms of OS and EFS, 
regardless of the other known risk factors, including MYCN 
amplification, INSS stage, and age at diagnosis. Overall, to 
date, p140Cap expression by IHC on NB samples has not 
been studied owing to lack of available cancer tissues, but 
SRCIN1 mRNA expression correlates with a good outcome 
and is an independent prognostic marker for NB [47].
Gene status and regulation of expression of SRCIN1 
in cancer
(A) The SRCIN1 and ERBB2 genes are co-amplified in a 
subset of human breast tumors. As shown above, the SRCIN1 
gene, located on Chromosome 17q12, is 1 million base pair 
centromeric to the ERBB2 gene. BAC array Comparative 
Genomic Hybridization (aCGH) on 200 ERBB2-amplified 
tumors revealed that SRCIN1 gene is altered in 70% of cases, 
with a copy number (CN) gain for SRCIN1 in 61.5% of the 
cases [15]. Relevantly, a Kaplan–Meier analysis showed that 
SRCIN1 amplification correlates with improved survival. 
Moreover, mRNA expression and SRCIN1 gene copy num-
ber were significantly correlated in 50 out of 200 ERBB2-
amplified tumors. Further, FISH analysis on an independ-
ent patient cohort showed that 56% of the ERBB2-amplified 
tumors specimens were also amplified for SRCIN1, while in 
ERBB2-negative BCs, SRCIN1 CN was never altered [15]. 
Overall, the SRCIN1 gene is frequently, but not necessarily, 
co-amplified with ERBB2 in BCs, following chromosomal 
Fig. 4  p140Cap expression in cancer patients correlates with good 
prognosis. a Kaplan–Meier curves for DRFI (left panel), and DRBC 
(right panel) stratified by p140Cap IHC expression in a cohort of 92 
ERBB2-positive patients [15]. b Kaplan–Meier curves for overall 
(left panel) and event-free (right panel) survival stratified by SRCIN1 
expression in a cohort of 498 NB patients [47]
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rearrangements which result in ERBB2 amplification, thus 
contributing to the biological heterogeneity of this BC 
subgroup [49]. Moreover, for the first time, the correlation 
with the positive patient outcome outlines that a gene in the 
ERBB2 amplicon may counteract ERBB2 oncogenic proper-
ties in BCs.
(B) SRCIN1 gene status in Neuroblastoma. The most fre-
quent chromosome imbalance in all high stage NBs is the 
17q gain, which occurs in 50–70% of cases [50, 51] and is 
associated with poor prognosis as an independent indicator 
of adverse outcome [52]. In 17 out of 225 NB patients with 
the 17q gain, the SRCIN1 gene status is altered, suggesting 
putative modifications of SRCIN1 gene expression in NB 
patients. However, the differences in OS between patients 
harboring these alterations does not reach statistical sig-
nificance (P = 0.5), indicating that the size of the cohort 
should be increased. However, the presence of translocation 
breakpoints involving the 17q portion and interrupting the 
SRCIN1 gene (heterozygous deletion or copy neutral-LOH) 
have been detected in primary tumors of all stages with 
17q gain, which associates a poor prognosis with NB [47]. 
SRCIN1 gene status is also affected in a panel of human NB 
cell lines. Indeed, SRCIN1 is lost in ACN, a neuroblast-like 
cell line derived from bone marrow metastasis [53], and a 
single copy is found in SH-SY-5Y, IMR-32, and HTLA-230 
cells, while function gain can be seen in LAN-1 cells, and 
subjected to copy neutral-LOH in SK-N-SH cells [47].
(C) SRCIN1 post-transcriptional regulation by miRNAs. 
MicroRNAs (miRNAs) are small non-coding RNAs which 
negatively regulate gene targets by affecting both mRNA sta-
bility or translation. Dysfunction of miRNAs is implicated 
in various human cancers and depending on their targeted 
genes, they can act as either oncogenes or tumor suppressor 
players [54, 55]. Recently, several papers have shown that 
p140Cap can be targeted by a variety of miRNAs in differ-
ent types of tumors such as lung, pancreatic, gastric, breast, 
ovarian and colorectal cancer as well hepatocellular and 
cervical carcinomas (Table 1). In almost all the cases, the 
direct targeting of p140Cap has been validated in cancer cell 
lines and the resulting downregulation of p140Cap expres-
sion promotes tumor features such as proliferation [56–68], 
migration [56, 58, 60, 61, 63, 67, 68], invasion [60, 64] and 
angiogenesis [69]. Among the reported miRNAs, miR-150 
has been described as a negative regulator of p140Cap in 
multiple malignancies such as BC, where it promotes migra-
tion, invasion and expression of EMT markers in cancer cells 
[70]. p140Cap protein levels are downregulated in cancer 
compared to adjacent non-cancer tissues and an opposite 
expression pattern has been observed for related miRNAs. 
Of note, high miR-371a expression is correlated with poor 
clinical pathological features of hepatocellular carcinoma, 
whereas decreased expression of p140Cap associates with 
adjacent organ invasion, microscopic vascular invasion, 
and advanced tumor stage [71]. Unlike p140Cap protein 
levels, mRNA abundance varies randomly in human lung 
cancer tissue samples, suggesting that miR-150 may regu-
late p140Cap by translational repression rather than by RNA 
degradation [56]. The increasing amount of data describing 
the inhibition of p140Cap expression by oncogenic miRNAs 
may lead to new therapeutic strategies that aim at restoring 
p140Cap levels and its tumor suppressor functions. How-
ever, additional efforts need to be made to better understand 
the relevance of p140Cap downregulation by miRNAs 
in vivo in preclinical studies.
p140Cap functional role in tumors
The correlation data described above for BC and NB patients 
lead to the hypothesis that p140Cap may attenuate the intrin-
sic biological aggressiveness of these tumors. Overall, 
p140Cap is able to limit the in vitro migration and invasion, 
as well as the in vivo tumor growth and metastasis formation 
of BC and NB models.
(A) Breast Cancer. p140Cap can regulate actin cytoskel-
eton and can interfere with cell spreading on the extracel-
lular matrix, during the early phases of cell adhesion of 
NIH3T3, ECV304 cells [3], and of MCF7 BC cells, mainly 
through its carboxy-terminal proline-rich region, involved 
in Src binding [11]. This defective cell adhesion may nega-
tively impact on migration ad invasion, as reported in triple 
negative MDA-MB-231 BC cells [11], and in ERBB2-pos-
itive SKBR3 and MDA-MB-453 cell lines [15]. However, 
p140Cap can also affect in vivo tumor growth. Indeed, the 
double transgenic mice NeuT-p140Cap, obtained by cross-
ing the MMTV-p140Cap transgenic mice with the MMTV-
NeuT mice, show a significant delay in the appearance of the 
Table 1  miRNAs targeting p140Cap
microRNAs Type of cancer References
miR-150 Lung cancer [56] Cao et al. 2014, [66] 
Zhang et al. 2018
Cervical carcinoma [68] Zhu et al. 2019
Breast cancer [70] Lu et al. 2019
Gastric cancer [62] Quan et al. 2019
miR-374a Gastric cancer [64] Xu et al. 2015
Pancreatic cancer [61] Ma et al. 2019
miR-211 Lung cancer [65] Ye et al. 2016
miR-873 Lung cancer [58] Gao et al. 2015
miR-32 Hepatocellular carcinoma [57] Chen et al. 2018
miR-181a Colorectal cancer [69] Sun et al. 2018
miR-371a Hepatocellular carcinoma [71] Bai et al. 2018
miR-510 Lung cancer [63] Wu et al. 2019
miR-208a Lung cancer [60] Liu et al. 2019
miR-665 Ovarian cancer [59] Li et al. 2019
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first tumor, associated with a significant decrease in the total 
tumor burden, compared to NeuT mice [15]. Local apop-
totic events within tumor development may also account for 
the difference in total tumor burden. Indeed, upon apoptotic 
stimuli and in 3D Matrigel-Collagen cultures, p140Cap 
cells showed increased sensitivity to apoptosis. Moreover, 
the ability of p140Cap-expressing tumor cells to activate an 
apoptotic program allows the cells to partially revert to a 
normal mammary tissue morphogenesis with the formation 
of an internal lumen, typical of normal mammary epithe-
lial cells [15, 72]. The ability of p140Cap in counteracting 
cancer cell invasion of secondary sites can be accounted 
for owing to the combination of impairment of cell adhe-
sion, migration and proliferation which is confirmed in both 
experimental and spontaneous metastasis assays [15, 35].
(B) Neuroblastoma. In NB cell lines, p140Cap affects 
in vitro migration and soft-agar growth, while, it correlates 
with a significant reduction in growth in in vivo xenografts, 
which is also confirmed by decreased IHC staining of the 
Ki67 proliferation marker, and a reduced number of spon-
taneous lung metastases [47]. It is to be pointed out that 
the quantification of several vascular markers highlighted 
a higher pericyte coverage, suggesting that p140Cap can 
impact on in vitro NB tumorigenic traits also by increasing 
tumor vessel stabilization.
p140Cap‑dependent signaling in tumors
(A) Breast cancer. p140Cap can control several signaling 
pathways in BC cells. The first to be identified was the 
down-regulation of the Src kinase activity, through the bind-
ing of the Csk protein, following cell matrix-adhesion or 
EGF stimulation [11, 19]. Upon association with p140Cap, 
Csk becomes activated and phosphorylates the Src Carboxy 
Terminal inhibitory tyrosine residue 527, which is enabled 
to associate the Src Amino Terminal SH2 domain, closing 
the active conformation of the molecule to an inactive state. 
As a consequence, p140Cap inhibits the downstream Src-
dependent phosphorylation of the Focal Adhesion Kinase 
(Fak), tyrosine 925, impairing the stability of Fak and Src 
association, and of the p130Cas adaptor protein [11].
In addition, p140Cap affects Rac1 GTPase activity [11]. 
Rac-specific GEFs, such as Dock, Tiam1 and PRex1, have 
also been shown to play a relevant role in BC [73, 74]. 
ERBB2-positive p140Cap tumor cells show a significant 
decrease in the activation of Tiam1 and of Rac [15]. The 
amino terminal region of p140Cap (1–287 amino acids) is 
sufficient for the association of full-length Tiam1, and the 
truncated catalytic domain of Tiam1 with a concomitant 
decrease in the Tiam1 activity. Moreover, in a large cohort of 
Her2-positive breast cancer patients, high levels of SRCIN1 
expression positively correlates with increased survival in 
patients with high TIAM1 expression [75]. These data also 
provide evidence of a new molecular complex made up of 
p140Cap, Tiam1 and E-cadherin at the cell membrane of 
ERBB2-positive tumor cells [75]. E-cadherin levels are 
highly down-regulated during the EMT (epithelial to mes-
enchymal transition) which controls the metastatic process 
[76, 77]. p140 tumor cells display up-regulation of both 
E-cadherin mRNA and cell surface protein levels [15]. The 
increased amount of immobilized E-cadherin at the cell 
surface relies on the impact of p140Cap on Csk/Src kinase 
mutual regulation [14]. Furthermore, p140Cap exerts an 
overall inhibitory effect on counteracting the EMT invasive 
program of ERBB2 tumors, as shown by a marked down-
regulation of the EMT transcription factors Snail, Slug and 
Zeb1 of an EMT transcription program, and of the mesen-
chymal cell–cell adhesion protein N-cadherin [15]. There-
fore, in addition to limiting Tiam1 activity, p140Cap could 
indeed contribute to strengthening the adherence junction 
stability through the stabilization of E-cadherin expression. 
Future studies will determine the way in which p140Cap 
participates in these molecular interactions in a spatial and 
temporal manner and affects E-cadherin junction stability, 
which is a key step in regulating tumor progression.
(B) Neuroblastoma. In ACN cells, p140Cap negatively 
regulates Src kinase activation as well as tyrosine phospho-
rylation of p130Cas, along with decreased phosphorylation 
of both STAT3 Tyr 705 (pSTAT3) and its upstream tyrosine 
kinase JAK2 [47]. Consistently, p140Cap silencing results in 
increased phosphorylation of Src and STAT3 in SH-SY-5Y, 
another well-characterized NB cell model. Interestingly, the 
overexpression of Src kinase has been associated with poor 
outcomes in NB patients [78], while its inhibition results 
in decreased proliferation and enhanced apoptosis in NB 
cells [79, 80]. Moreover, STAT3 can exert a pro-survival 
role in NB [81–83]. In line with this, p140Cap cells has 
shown decreased levels of the survival marker Bcl2 as well 
as increased Annexin V staining, after anoikis [47].
The increased survival of p140Cap-expressing NB 
patients could be explained as there being increased cell 
sensitivity to chemotherapy. Interestingly, p140 NB cells 
has shown significantly increased sensitivity to low doses 
(10, 100 nM) of doxorubicin and etoposide, two drugs 
used in NB first-line treatments. Consistently, in SH-SY-
5Y cells, p140Cap silencing results in increased viability to 
both drugs. Both etoposide and doxorubicin prevent repair 
of the DNA strands, stopping the process of replication. 
In line with this, p140Cap NB cells harbor a significant 
increase foci/cell number in phosphorylated histone H2AX 
gamma, an established marker of DNA damage [84]. Over-
all, p140Cap NB cells display a significant decrease in cell 
viability to chemotherapy drugs, with an increased sensitiv-
ity to drug-dependent DNA damage. Furthermore, sensitiv-
ity of NB cells to doxorubicin and etoposide is additionally 
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enhanced when used in combination with Saracatinib and 
Sugen, two well-known Src inhibitors. Combined regimens 
acted synergistically both in control and p140Cap-express-
ing NB cells; however, p140Cap cells has shown further 
increased sensitivity to the Src inhibitors in combined treat-
ments, suggesting that chemotherapy and Src inhibitor com-
bination synergistically decreases NB cell viability and this 
effect can be further increased by p140Cap expression. In 
addition to Src activity downregulation, p140Cap ability to 
associate with proteins belonging to multiple pathways can 
contribute to the increased sensitivity of p140Cap NB cells 
to combined treatments.
p140Cap interactome in breast cancer and related 
signaling pathways
The assembly of multi-protein complexes (interactomes) is 
essential for carrying out basic biological functions, such as 
cell migration and proliferation, in which protein–protein 
interactions are built around adaptor proteins, at the plasma 
membrane level, in the cytoplasm, or in specific organelles. 
In healthy neuronal synapses, the molecular complexes and 
pathways underlying p140Cap function in pathological and 
physiological conditions have been interrogated using mass 
spectrometry (MS) combined with bioinformatics data and 
analyses. Interestingly, the p140Cap interactome in crude 
synaptosome revealed 351 p140Cap interactors which clus-
ter to sub complexes mostly located in the postsynaptic den-
sity (PSD) [19]. The p140Cap interactome was also recently 
generated in ERBB2-positive BC cells [15, 85], leading to 
the identification of 373-interacting proteins. Consistent with 
the previously described role for p140Cap in cell–matrix 
and cell–cell adhesion, and with the already known inter-
actors, the GO Ontology has shown significant enrichment 
for “Cell- substrate junction” and “Focal adhesion” terms 
[11, 14]. However, a previously unknown role for p140Cap 
complexes in protein homeostasis in BC emerges from the 
terms “Proteasome complex”, “Endopeptidase complex” and 
“Extrinsic component of plasma membrane”. In the enrich-
ment analysis of GO Biological Process (BP) terms and in 
the Reactome pathway database, “Regulation of mRNA sta-
bility”, “Response to tumor necrosis factor” and other terms 
related to regulation of protein translation, DNA and RNA 
damage response, apoptosis and cell cycle were highly sig-
nificant. It is worth noting that p140Cap interactome takes 
part in the “Wnt signaling pathway, planar cell polarity path-
way”, a fundamental regulator of cell proliferation in cancer 
cells [86].
The Protein–Protein Interaction (PPI) Networks can be 
challenged by clustering algorithms and parameters to iden-
tify heterogeneous communities within the network, which 
often form ‘modules’ of proteins that functionally co-oper-
ate in specific pathways. Gene-disease and gene-functional 
annotation data can then be marked on those clusters to test 
functional/disease enrichment of the clusters. Within the 
p140Cap interactome, 15 communities were present, with a 
topology-functional relationship which allowed the identifi-
cation of subsets of proteins which preferentially contribute 
to specific functions. For example, the Cluster C2 contains 
p140Cap and the tyrosine kinases Src and ERBB2, rein-
forcing the concept that p140Cap can associate and regulate 
tyrosine kinases [11, 87], which play key roles in BC trans-
formation and progression.
Conclusions and future perspectives
Based on the collected data, p140Cap shows tumor-sup-
pressing properties, which oppose and interfere with can-
cer features in human malignancies. p140Cap expression 
Fig. 5  Impact of SRCIN1/
p140Cap gene alteration in 
ERBB2/HER2-amplified breast 
cancer and neuroblastoma. 
Amplification of the SRCIN1 
gene in ERBB2/HER-2-positive 
breast cancer patients impairs 
tumor growth and metastasis 
mainly through the down-
regulation of Tiam1/Rac1 axis. 
SRCIN1 aberrant alterations 
such as translocations, dele-
tions or loss of heterozygo-
sity promote tumor growth, 
metastasis and drug resistance 
in NB patients, consistent with 
the loss of p140Cap expression, 
and inhibition of both Src and 
STAT3/Jak2 pathways
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correlates with a good prognosis and a delay in tumor pro-
gression in BC and NB patients (Fig. 5). However, further 
analysis is needed of SRCIN1 gene status and p140Cap power 
as diagnostic tools in specific cancer subtypes to address its 
real contribution to the biological heterogeneity of human 
tumors in terms of patient stratification. Several molecular 
pathways have already been depicted through which p140Cap 
may exert its tumor suppressing properties, but the extensive 
analysis of p140Cap interactome in BC cells have recently 
provided data on its involvement in several additional bio-
logical networks relevant for cancer progression. Moreover, 
p140Cap expression confers at least in NB cells a higher sen-
sitivity to chemotherapeutic drugs, implying its impact on 
cytoskeletal features and pro-apoptotic processes involved in 
chemotherapy-induced cell death. In addition, more preclini-
cal work is needed to understand whether p140Cap-express-
ing tumors might be treated with low doses of drugs or with 
drug combination regimens. Detailed molecular analysis on 
these pathways will pave the way for the identification of key 
p140Cap-dependent mechanisms, including its interacting 
proteins, as suitable targets for cancer treatment. On the other 
hand, since many tumors do not express relevant levels of 
p140Cap, the existing knowledge on miRNAs able to down-
regulate p140Cap expression in human tumors, provides the 
testable hypothesis on the use of specific anti-miRNAs to 
enhance an appropriate tumor response in preclinical mod-
els. It remains to be determined whether p140Cap-regulated 
pathways might also impact on tumor microenvironment, and 
on tumor cell metabolism. Overall, the dissection of p140Cap 
biological features and its regulated pathways in cancer 
highlight the potential clinical impact of SRCIN1/p140Cap 
expression on patient stratification, as being the relevant key 
player for patient outcome.
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